Luye Pharma Begins Phase 1 Trial for Triple-Target Antidepressant
August 04, 2025 | 08:00
A new dawn for mental health as Luye takes aim at NET, DAT, and GABA pathways.
Luye Pharma Launches ERZOFRI® in U.S. for Schizophrenia Treatment
April 07, 2025 | 14:04
Luye Pharma Group today announced that ERZOFRI® extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy for the treatment of adults with schizoaffective disorder.
Mobile Version